BACKGROUND: The clinical outcome of patients with myocardial infarction (MI) complicated by cardiogenic shock (CS) who require mechanical ventilation (MV) is poor. OBJECTIVE: To analyze the impact of abciximab pretreatment in this high-risk population of MI patients. METHODS: The present study was a retrospective subanalysis of the multicentre randomized Routine Upfront Abciximab Versus Standard Peri-Procedural Therapy in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock (PRAGUE-7) study, which included 80 MI patients in CS undergoing primary percutaneous coronary intervention (PCI). Patients were randomly assigned into group A (routine pretreatment with an abciximab bolus followed by a 1 h abciximab infusion) and group B (standard therapy). The subanalysis included 37 patients requiring MV. Seventeen patients were in group A and 20 were in group B. The primary end point (death/stroke/reinfarction/new severe renal failure) at 30 days, procedural success (thrombosis in myocardial infarction [TIMI] flow) and frequency of bleeding were assessed. The χ(2) and Student's t tests were used for statistical analysis; P<0.05 was considered to be statistically significant. RESULTS: The primary end point occurred in nine (53%) patients in group A and 12 (60%) patients in group B (P=0.66). TIMI flow after primary PCI was higher in group A (2.75 versus 2.31; P<0.05). Major bleeding occurred in 12% of patients in group A versus 10% of patients in group B (P=0.86). Minor or minimal bleeding was more common in group A (29%) compared with group B (5%; P<0.05). CONCLUSION: The results of the present study suggest that routine pretreatment with abciximab before primary PCI in mechanically ventilated patients with MI complicated by cardiogenic shock was associated with better angiographic results but also with a higher incidence of bleeding.

Department of Cardiology University Hospital Plzen Faculty of Medicine Plzen;

Zobrazit více v PubMed

Babaev A, Frederick PD, Pasta DJ, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2005;294:448–54. PubMed

Goldberg RJ, Spencer FA, Gore JM, et al. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: A population-based perspective. Circulation. 2009;119:1211–9. PubMed PMC

Fox KA, Steg PG, Eagle KA, et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999–2006. JAMA. 2007;297:1892–900. PubMed

Czarnecki A, Welsh RC, Yan RT, et al. Reperfusion strategies and outcomes of ST-segment elevation myocardial infarction patients in Canada: Observations from the Global Registry of Acute Coronary Events (GRACE) and the Canadian Registry of Acute Coronary Events (CANRACE) Can J Cardiol. 2012;28:40–7. PubMed

Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA. 2006;295:2511–5. PubMed PMC

Stegman BM, Newby LK, Hochman JS, et al. Post-myocardial infarction cardiogenic shock is a systemic illness in need of systemic treatment: Is therapeutic hypothermia one possibility? J Am Coll Cardiol. 2012;59:644–7. PubMed

Buerke M, Lemm H, Dietz S, et al. Pathophysiology, diagnosis, and treatment of infarction-related cardiogenic shock. Herz. 2011;36:73–83. PubMed

ASSENT-4 PCI investigators Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): Randomised trial. Lancet. 2006;367:569–78. PubMed

Ellis SG, Tendera M, de Belder MA, et al. FINESSE Investigators Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008;358:2205–17. PubMed

Tousek P, Rokyta R, Tesarova J, et al. Routine upfront abciximab versus standard periprocedural therapy in patiens undergoing primary percutaneous coronary intervention for cardiogenic shock: The PRAGUE-7 Study. An open randomized multicentre study. Acute Cardiac Care. 2011;13:116–22. PubMed

Bilkova D, Motovska Z, Widimsky P, et al. Shock index: A simple clinical parameter for quick mortality risk assessment in acute myocardial infarction. Can J Cardiol. 2011;27:739–42. PubMed

Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis In Myocardial Infarction (TIMI) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987;76:142–54. PubMed

Hochman JS, Buller ChE, Sleeper LA, et al. Cardiogenic shock complicating acute myocardial infarction – etiologies, management and outcome: A report from the SHOCK Trial Registry. J Am Coll Cardiol. 2000;36:1063–1070. PubMed

Thiele H, Zeymer U, Neumann FJ, et al. the IABP-SHOCK II Trial Investigators Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367:1287–96. PubMed

O’Connor ChM, Rogers JG. Evidence for overturning the guidelines in cardiogenic shock. N Engl J Med. 2012;267:1349–50. PubMed

Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) Eur Heart J. 2012;33:2569–619. PubMed

Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading. Circulation. 2009;119:1933–40. PubMed

Kastrati A, Mehilli J, Neumann FJ, et al. Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment 2 Trial Investigators Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 randomized trial. JAMA. 2006;295:1531–8. PubMed

Soucková L, Opatrilová R, Suk P, et al. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR) Eur J Clin Pharmacol. 2013;69:309–17. PubMed

Osmancik P, Jirmar R, Hulikova K, et al. A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheter Cardiovasc Interv. 2010;75:158–66. PubMed

Thiele H, Wöhrle J, Hambrecht R, et al. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: A randomised trial. Lancet. 2012;379:923–31. PubMed

Suh JW, Mehran R, Claessen BE, et al. Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction: The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. Am Coll Cardiol. 2011;58:1750–6. PubMed